Group 1: Market Overview - The market experienced a decline with major indices closing lower: Shanghai Composite Index down 0.70%, Shenzhen Component Index down 1.27%, and ChiNext Index down 1.41% [1] - Sectors showing gains included superconductors, controllable nuclear fusion, and non-metallic materials, while real estate services, real estate development, and commercial retail sectors faced declines [1] - Main capital inflows were observed in controllable nuclear fusion, superconductors, and wind power equipment industries [1] Group 2: Commercial Aerospace Investment - Guojin Securities noted that China is at a pivotal moment similar to SpaceX's network formation phase from 2018 to 2020, with a shift from custom satellite manufacturing to mass production [1] - The upcoming launch of the Wenchang Super Satellite Factory and SpaceX's planned IPO next year indicate a significant acceleration in global commercial aerospace investment and industrialization [1] - Key investment areas include commercial aerospace, low-altitude economy, and military trade, with advancements in reusable rocket technology expected to lower launch costs and accelerate satellite constellation deployment [1] Group 3: Consumer Market Trends - Multiple regions have introduced policies to boost consumption, with Jiangsu's "14th Five-Year Plan" focusing on expanding and upgrading consumer goods, particularly in automobiles and home appliances [2] - Haitong Securities highlighted a structural growth opportunity in the consumer sector driven by technological advancements and the emergence of new consumption trends, such as trendy toys and beauty products [2] - The outlook for 2026 suggests that ongoing consumption policies will stimulate supply and demand, leading to a steady recovery in domestic demand [2] Group 4: Innovation in Pharmaceuticals - Aijian Securities expressed optimism about the trend of Chinese innovative drugs entering international markets, noting that A/H innovative drug companies' valuations have returned to reasonable levels after adjustments [2] - The focus for 2026 will be on investment opportunities in key areas such as antibody-drug conjugates (ADC), bispecific antibodies, small nucleic acids, and weight-loss drugs [2] - CITIC Securities indicated that innovative drugs are expected to be a major upward trend in the cross-year market, supported by China's pharmaceutical industry's transition to "innovation realization + global layout" [3]

Core Viewpoint - The article discusses the imminent adjustment period for the Hong Kong Stock Connect, highlighting the potential inclusion of 31 new stocks, including Jinfang Pharmaceutical, which is expected to meet the entry criteria due to its stable market performance [1][2]. Group 1: Company Performance - Jinfang Pharmaceutical's average market capitalization during the review period is reported at HKD 10.296 billion, exceeding the threshold of HKD 9.242 billion by over HKD 1 billion, indicating a strong likelihood of inclusion in the upcoming adjustment [2]. - The stock experienced significant volatility post-IPO, with a peak increase of 115.79% from the issue price, followed by a decline of 29.31% over a month, reflecting market fluctuations and investor sentiment [3][10]. - After reaching a market cap below HKD 10 billion on October 22, the stock quickly stabilized, avoiding further price bubble risks, aided by its IPO structure which limited short-term selling pressure from retail investors [11]. Group 2: Market Context - The Hong Kong innovative drug sector has seen a substantial rally, with the Hang Seng Healthcare Index rising from a low of 2152.38 points to a high of 4726.41 points, marking a maximum increase of 119.59% over eight months [10]. - Jinfang Pharmaceutical's IPO was highly successful, with a subscription rate of 2662.79 times for the public offering, reflecting strong institutional interest in the KRAS inhibitor sector [10]. - The stock's performance is also influenced by broader market trends, as the Hang Seng Healthcare Index experienced an 11.05% correction in October, impacting investor behavior and contributing to Jinfang's price volatility [10]. Group 3: Technical Analysis - Following a significant drop on October 22, Jinfang Pharmaceutical's stock price rebounded sharply, indicating strong buying interest and a potential shift in market sentiment [4][6]. - The stock has entered a phase of stable horizontal consolidation, with a high concentration of shares held by investors, which reduces the likelihood of significant price fluctuations in the near term [6]. - The average cost of shares held by investors remains around HKD 37, which is significantly above the current market price, further discouraging selling and stabilizing the stock [6].

Core Viewpoint - The current market is transitioning from high growth to moderate growth, with a trend of convergence between technology and value sectors in the new cycle [1] Group 1: Market Cycle Analysis - Understanding cyclical changes is essential for future market judgments, with significant shifts observed over the past two decades [2] - The first phase (2000-2010) was dominated by cyclical growth, benefiting heavy industries, resource sectors, and low-end manufacturing [3] - The second phase (2010-2021) saw a shift towards growth, driven by urbanization and the rise of consumer demand and emerging services, with the ChiNext index experiencing rapid growth [3] - Since 2021, the market has gradually shifted back to moderate growth, with value styles regaining dominance, as evidenced by the performance of the STAR Market index compared to the CSI Dividend Index [3] - Long-term migration of industry weights indicates structural upgrades, with technology, consumer healthcare, and cyclical finance gaining share in the CSI 300 over the past 16 years [3] Group 2: Future Outlook for 2026 - The outlook for 2026 is summarized by three keywords: technology leading, value following, and returning to leaders, based on long-term industry structural evolution [4] - The current AI narrative, represented by the STAR Market, mirrors the technology cycle from 2011 to 2015, but with different supporting backgrounds such as demographic changes and geopolitical factors [4] - Key signals for market improvement include PPI and inventory conditions, with expectations for corporate performance to improve in mid-2024 following a low PPI point [4][5] Group 3: Investment Directions - The market is witnessing a recovery in value sectors, which may present structural opportunities in 2026, especially after a year of significant underperformance compared to growth sectors [6] - Investment focus will include cyclical industries (oil, coal, basic metals), non-banking sectors (insurance, brokerage), high ROE industries (internet, traditional consumption), and new cycle industries (new energy, power equipment) [6] - Continuous themes may emerge in CXO, innovative pharmaceuticals, AI applications, and humanoid robotics, although market volatility is expected to increase [6] Group 4: Research and Investment Strategy - The exponential growth of fund numbers, asset management scale, and listed companies has increased information density, posing challenges for research and investment [7] - The company is developing a systematic investment approach through professional division of labor and industrialized production lines to meet client needs [7] - AI is anticipated to become a core capability in active management, fundamentally reshaping the research and investment chain over the next three years [7]

Core Viewpoint - The A-share market experienced significant activity on December 11, with a total of 38 stocks reaching their daily limit up, indicating strong investor interest in specific sectors, particularly in commercial aerospace and technology [1] Group 1: Stock Performance - Multiple commercial aerospace stocks achieved consecutive limit-up performances, highlighting a growing trend in this sector [1] - Zais Technology recorded four consecutive limit-ups, indicating robust market confidence in its business prospects [1] - Sichuan Jinding and Lianang Micro both achieved two consecutive limit-ups, reflecting positive investor sentiment towards their respective sectors [1] Group 2: Sector Highlights - The stocks that reached limit-up included those from various sectors such as warehousing and logistics, paper manufacturing, automotive parts, innovative pharmaceuticals, humanoid robotics, and cross-border e-commerce [1] - The commercial aerospace sector showed notable strength, with several companies, including Zais Technology and *ST Chengchang, performing well [1] - The robotics sector also saw positive movement, with companies like Sichuan Jinding and Nandu Property achieving consecutive limit-ups [1]

Core Viewpoint - The A-share market is expected to experience relative fluctuations towards the end of the year, with anticipation for new policies and signals that may influence market direction for the upcoming year [1][3]. Group 1: Market Outlook - After the significant rise in the first three quarters, various sectors have shown substantial performance, particularly in the TMT sector, which is currently experiencing high levels of institutional holdings and crowded trading [1][3]. - The overall sentiment in the AI sector remains strong, suggesting continued interest and investment potential [1][3]. Group 2: Investment Focus - The company will actively focus on growth stocks, particularly in the following areas: - The Hong Kong technology and internet sector, which has reasonable valuations post-adjustment [1][3]. - Sub-industries benefiting from AI technology, including hardware infrastructure, robotics, intelligent driving, and AI edge applications [1][3]. - Growth-oriented consumer sub-industries, such as innovative pharmaceuticals, gaming, and overseas consumer products [1][3]. Group 3: Robotics Sector - The robotics sector is anticipated to see significant catalysts from now until the first quarter of next year, including the launch and mass production plans of new-generation robots by leading overseas companies and the listing processes of domestic leading robotics firms [4]. - Both industry and policy developments are expected to progress, indicating that the sector may enter a phase of accelerated mass production, which is worth close attention [4].

Group 1 - The Federal Reserve has lowered interest rates by 25 basis points, boosting market sentiment and leading to a significant increase in trading activity in the Hong Kong stock market, particularly in the Hang Seng Innovative Drug ETF (520500) [1] - Recent favorable developments in the innovative drug sector include the release of the first commercial insurance innovative drug directory and the launch of the Chinese drug price registration system, which are expected to enhance the global development of domestic innovative drugs [1] - The head of the National Medical Products Administration emphasized the importance of supporting pharmaceutical companies in innovation and the optimization of regulatory policies to promote high-quality development in the pharmaceutical industry [1] Group 2 - The market's confidence in the long-term development of the innovative drug sector is expected to strengthen, leading to increased investments, with the Hang Seng Innovative Drug ETF (520500) seeing a total inflow of 165 million yuan over three trading days [2] - The Hang Seng Innovative Drug ETF (520500) tracks an index that includes companies involved in the research, development, and production of innovative drugs, focusing on firms with strong R&D capabilities [2] - The top five constituents of the index as of December 10, 2025, include China Biologic Products, CanSino Biologics, BeiGene, Innovent Biologics, and Kelun-Biotech [2] Group 3 - Since September 2025, the Hong Kong innovative drug sector has experienced a noticeable correction, but the combination of policy support and a loose liquidity environment may open new development opportunities [3] - The Hang Seng Innovative Drug ETF (520500) is characterized by its large scale, good liquidity, and support for T+0 trading, making it an effective tool for investors looking to capitalize on opportunities in the Hong Kong innovative drug sector [3]

Core Viewpoint - The Federal Reserve's decision to cut interest rates by 25 basis points has positively impacted market sentiment, particularly in the Hong Kong stock market, leading to increased trading activity in the Hang Seng Innovative Drug ETF (520500) [1][4] Group 1: Market Response - Following the Fed's rate cut, the Hong Kong stock market opened higher, with the Hang Seng Innovative Drug ETF (520500) recording a trading volume of 407 million yuan by 11:25 AM [1][4] - The innovative drug sector has received multiple positive developments, including the release of the first commercial insurance innovative drug directory and the launch of the Chinese drug price registration system, which are expected to boost the sector [1][4] Group 2: Regulatory Support - The head of the National Medical Products Administration emphasized the importance of supporting pharmaceutical companies in innovation and the optimization of regulatory policies to facilitate high-quality development in the pharmaceutical industry [2][5] - The market's confidence in the long-term development of the innovative drug sector is expected to strengthen, leading to increased investments in the Hang Seng Innovative Drug ETF (520500), which saw a total inflow of 165 million yuan over three trading days [2][5] Group 3: ETF Performance - The Hang Seng Innovative Drug ETF (520500) has reached a historical high in terms of shares, totaling 1.209 billion shares and a scale of 2.022 billion yuan as of December 10, 2025 [2][5] - The ETF tracks an index that includes companies involved in innovative drug research, development, and production, focusing on firms with strong R&D capabilities [2][5] Group 4: Investment Opportunity - Since September 2025, the Hong Kong innovative drug sector has experienced a noticeable pullback, but the combination of policy support and liquidity easing is expected to create new development opportunities [2][5] - The Hang Seng Innovative Drug ETF (520500) is positioned as an efficient tool for investors looking to capitalize on opportunities in the Hong Kong innovative drug sector due to its large scale and favorable liquidity [2][5]

Group 1 - The core viewpoint of the report highlights that the pharmaceutical industry in China is experiencing a reversal in 2025, driven by innovative drugs, with significant benefits observed in the CXO and upstream supply chain sectors, particularly in the Hong Kong stock market where innovative drugs have seen a rise of over 80% year-to-date [1][4] - The report emphasizes that the core catalyst for innovative drugs comes from policy support and the realization of business development (BD) opportunities abroad, with notable transactions exceeding 1 billion USD, validating the international competitiveness of Chinese innovative drugs [1][2] - A significant reform in the payment sector is underway, with the introduction of a dual-track system for medical insurance, allowing for the inclusion of high-value innovative drugs in commercial insurance, addressing the gap in coverage for expensive treatments [1][2] Group 2 - The report indicates a rapid growth trend in the number of license-out transactions by Chinese pharmaceutical companies, with total upfront payments reaching 6.298 billion USD, a 53% year-on-year increase, and total transaction amounts reaching 118.862 billion USD, a 125% increase [2] - Looking ahead to 2026, the report suggests a shift from "BD-driven" to "data-driven" investment in innovative drugs, emphasizing the importance of clinical data validation and commercial capabilities for revenue growth [2] - Recommended stocks for investment include Heng Rui Medicine, Kelun-Biotech, and Teva Biopharmaceuticals, among others, while companies like Kangfang Biotech and Innovent Biologics are suggested for further attention [2][3] Group 3 - The overall profitability of the pharmaceutical sector remains stable, with a gradual improvement in the profitability of the pharmaceutical manufacturing industry, despite a slight decline in revenue growth [11][15] - The report notes a significant divergence within the industry, with the medical services sector performing well, while the profits of the biopharmaceutical sector have seen a substantial decline [28][29] - The report highlights that the medical insurance fund's income and expenditure growth rates are stabilizing, indicating a long-term trend towards cost control in medical insurance, which is essential for the sustainable development of the innovative drug industry [31][36]

6 证券研究报告 点评报告 2025 年 12 月 11 日 晨会纪要 核[心Ta观bl点e_：Summary] 一、宏观经济组： 事件 1： 12 月 10 日早 9 点半国家统计局公布 11 月中国物价数据。 评论 1： 中国 11 月 CPI 同比为 0.7%，预期为 0.7%，前值 10 月为 0.2%；核心 CPI 同比为 1.2%，， 前值为 1.2%。11 月 CPI 环比为-0.1%，前值为 0.2%，去年同期是-0.6%，可见 11 月 CPI 同比的回升主要受基数的影响；核心 CPI 环比同样为-0.1%，前值为 0.2%。 由于 CPI 的回升，核心 CPI 与 CPI 之间同比差距，由上月 1%缩小至 0.5%。 11 月食品环比为 0.5%，前值为 0.3%，而去年同期是-2.7%。其中，鲜菜环比上涨 7.2%，是影响 CPI 同比回升的关键因素；而猪肉下跌 2.2%，蛋类和水产品环比均 下跌 1.8%，鲜果下跌 0.3%。 11 月非食品环比为-0.2%，前值为 0.2%。其中，其它用品和服务环比上涨 1.2%， 衣着上涨 0.7%，医疗保健环比上涨 0.1%；而交通通讯环比下跌 ...

Demand Side Analysis - The overall domestic demand is showing a slow recovery trend, with significant investment opportunities concentrated in areas with new incremental demand, where innovation is the core driving force [2][5] - Innovation can uncover unmet domestic needs and assist companies in expanding into overseas markets, with the innovative drug sector expected to continue releasing potential [2][5] - The overseas market potential for domestic high-quality medical device companies is substantial, with some leading companies having nearly 50% of their revenue from overseas, while their global market share is only about 3% [2][5] Supply Side Analysis - Although overall investment opportunities on the supply side are not as abundant as on the demand side, there are still structural opportunities [3][6] - The past few years of slowed domestic demand growth have led to operational pressures in many industries, prompting supply-side clearing and optimization of competitive landscapes [3][6] - Companies that have survived the industry downturn are expected to exhibit stronger resilience and significant growth elasticity in the next demand recovery cycle [3][6] - Specific investment targets in the traditional pharmaceutical industry include areas such as traditional Chinese medicine, pharmacies, and third-party diagnostics, where significant changes on the supply side can be identified [3][6]